GPSVFPLAPSSK-13C6,15N2

GPSVFPLAPSSK-13C6,15N2 is the 13C- and 15N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies[1][2].

Product Specifications

CAS Number

[2077176-84-0]

UNSPSC

12352209

Target

Isotope-Labeled Compounds; SARS-CoV

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/gpsvfplapssk-13c6.html

Solubility

10 mM in DMSO

Smiles

O=C([C@H]1N(CCC1)C(CN)=O)N[C@@H](CO)C(N[C@@H](C(C)C)C(N[C@@H](CC2=CC=CC=C2)C(N3[C@@H](CCC3)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N4[C@@H](CCC4)C(N[C@@H](CO)C(N[C@@H](CO)C([15NH][13C@H]([13C](O)=O)[13CH2][13CH2][13CH2][13CH2][15NH2])=O)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C49 13C6H87N11 15N2O16

Molecular Weight

1194.30

References & Citations

[1]de Jong KAM, et al. Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS. J Pharm Biomed Anal. 2021 Oct 25;205:114319. |[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-226.